Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect

Dendritic cells (DCs) are immune specialized cells playing a critical role in promoting immune response against antigens, and may represent important targets for therapeutic interventions in cancer. DCs can be stimulated ex vivo with pro-inflammatory molecules and loaded with tumor-specific antigen(...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sara Nava, Daniela Lisini, Simona Frigerio, Anna Bersano
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	dendritic cells immunotherapy cancer adjuvant therapy Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/49f7a6990a9644eca8b165bba329a7dd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:49f7a6990a9644eca8b165bba329a7dd
record_format	dspace
spelling	oai:doaj.org-article:49f7a6990a9644eca8b165bba329a7dd2021-11-25T17:55:33ZDendritic Cells and Cancer Immunotherapy: The Adjuvant Effect10.3390/ijms2222123391422-00671661-6596https://doaj.org/article/49f7a6990a9644eca8b165bba329a7dd2021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/22/12339https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Dendritic cells (DCs) are immune specialized cells playing a critical role in promoting immune response against antigens, and may represent important targets for therapeutic interventions in cancer. DCs can be stimulated ex vivo with pro-inflammatory molecules and loaded with tumor-specific antigen(s). Protocols describing the specific details of DCs vaccination manufacturing vary widely, but regardless of the employed protocol, the DCs vaccination safety and its ability to induce antitumor responses is clearly established. Many years of studies have focused on the ability of DCs to provide overall survival benefits at least for a selection of cancer patients. Lessons learned from early trials lead to the hypothesis that, to improve the efficacy of DCs-based immunotherapy, this should be combined with other treatments. Thus, the vaccine’s ultimate role may lie in the combinatorial approaches of DCs-based immunotherapy with chemotherapy and radiotherapy, more than in monotherapy. In this review, we address some key questions regarding the integration of DCs vaccination with multimodality therapy approaches for cancer treatment paradigms.Sara NavaDaniela LisiniSimona FrigerioAnna BersanoMDPI AGarticledendritic cellsimmunotherapycanceradjuvant therapyBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 12339, p 12339 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	dendritic cells immunotherapy cancer adjuvant therapy Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	dendritic cells immunotherapy cancer adjuvant therapy Biology (General) QH301-705.5 Chemistry QD1-999 Sara Nava Daniela Lisini Simona Frigerio Anna Bersano Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect
description	Dendritic cells (DCs) are immune specialized cells playing a critical role in promoting immune response against antigens, and may represent important targets for therapeutic interventions in cancer. DCs can be stimulated ex vivo with pro-inflammatory molecules and loaded with tumor-specific antigen(s). Protocols describing the specific details of DCs vaccination manufacturing vary widely, but regardless of the employed protocol, the DCs vaccination safety and its ability to induce antitumor responses is clearly established. Many years of studies have focused on the ability of DCs to provide overall survival benefits at least for a selection of cancer patients. Lessons learned from early trials lead to the hypothesis that, to improve the efficacy of DCs-based immunotherapy, this should be combined with other treatments. Thus, the vaccine’s ultimate role may lie in the combinatorial approaches of DCs-based immunotherapy with chemotherapy and radiotherapy, more than in monotherapy. In this review, we address some key questions regarding the integration of DCs vaccination with multimodality therapy approaches for cancer treatment paradigms.
format	article
author	Sara Nava Daniela Lisini Simona Frigerio Anna Bersano
author_facet	Sara Nava Daniela Lisini Simona Frigerio Anna Bersano
author_sort	Sara Nava
title	Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect
title_short	Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect
title_full	Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect
title_fullStr	Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect
title_full_unstemmed	Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect
title_sort	dendritic cells and cancer immunotherapy: the adjuvant effect
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/49f7a6990a9644eca8b165bba329a7dd
work_keys_str_mv	AT saranava dendriticcellsandcancerimmunotherapytheadjuvanteffect AT danielalisini dendriticcellsandcancerimmunotherapytheadjuvanteffect AT simonafrigerio dendriticcellsandcancerimmunotherapytheadjuvanteffect AT annabersano dendriticcellsandcancerimmunotherapytheadjuvanteffect
_version_	1718411799643029504

Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect

Ejemplares similares